{
  "id": "5c72bd047c78d69471000077",
  "type": "yesno",
  "question": "Can pazopanib be used for treatment von Hippel-Lindau disease?",
  "ideal_answer": "Yes, pazopanib is used for treatment von Hippel-Lindau disease.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/26497655",
    "http://www.ncbi.nlm.nih.gov/pubmed/29396065",
    "http://www.ncbi.nlm.nih.gov/pubmed/30236511",
    "http://www.ncbi.nlm.nih.gov/pubmed/22374327"
  ],
  "snippets": [
    {
      "text": "Variable response of CNS hemangioblastomas to Pazopanib in a single patient with von Hippel-Lindau disease: Case report.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29396065",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Treatment of RCCs with tyrosine kinase inhibitors (TKIs) such as Pazopanib is now first line therapy, but their effect on VHL-associated CNS HBs remains unknown. We report the use of Pazopanib in a patient with VHL disease for treatment of RCC who also harbored multiple CNS HBs. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29396065",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Pazopanib in patients with von Hippel-Lindau disease: a single-arm, single-centre, phase 2 trial.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30236511",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "INTERPRETATION: Pazopanib was associated with encouraging preliminary activity in von Hippel-Lindau disease, with a side-effect profile consistent with that seen in previous trials. Pazopanib could be considered as a treatment choice for patients with von Hippel-Lindau disease and growing lesions, or to reduce the size of unresectable lesions in these patients. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30236511",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Recurrent multiple CNS hemangioblastomas with VHL disease treated with pazopanib: a case report and literature review.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26497655",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": " Here, we report a 37-year-old woman's case with recurrent and rapidly progressive VHL-associated hemangioblastomas, causing severe disability. She was treated 24 months with pazopanib, a multityrosine kinase inhibitor (TKI) targeting VEGF and PDGF-\u03b2 pathways. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26497655",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Pazopanib therapy for cerebellar hemangioblastomas in von Hippel-Lindau disease: case report.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22374327",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Here we provide the first report demonstrating clinical and radiological anti-tumor response using pazopanib, a small molecule multi-receptor tyrosine kinase inhibitor, in a patient with treatment-refractory VHL-associated CNS hemangioblastoma. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22374327",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Pazopanib could be considered as a treatment choice for patients with von Hippel-Lindau disease and growing lesions, or to reduce the size of unresectable lesions in these patients.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30236511",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "METHODS\nIn this non-randomised, single-centre, open-label, phase 2 trial, adult patients with clinical manifestations of von Hippel-Lindau disease were recruited from the University of Texas MD Anderson Cancer Center (Houston, TX, USA) and were treated with pazopanib (800 mg orally daily) for 24 weeks, with an option to continue treatment if desired by the patient and treating physician.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30236511",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "We aimed to assess the activity and safety of pazopanib in patients with von Hippel-Lindau disease.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30236511",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "INTERPRETATION\nPazopanib was associated with encouraging preliminary activity in von Hippel-Lindau disease, with a side-effect profile consistent with that seen in previous trials.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30236511",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "FINDINGS\nBetween Jan 18, 2012, and Aug 10, 2016, we screened 37 patients with genetically confirmed or clinical features consistent with von Hippel-Lindau disease, of whom 31 eligible patients were treated with pazopanib.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30236511",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Pazopanib therapy for cerebellar hemangioblastomas in von Hippel-Lindau disease: case report.von Hippel-Lindau (VHL) disease is a genetically acquired multisystem tumor syndrome of the viscera and central nervous system (CNS). ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22374327",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Recurrent multiple CNS hemangioblastomas with VHL disease treated with pazopanib: a case report and literature review.Hemangioblastoma is a rare benign neoplasm, accounting for less than 2% of all primitive brain tumors. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26497655",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "We aimed to assess the activity and safety of pazopanib in patients with von Hippel-Lindau disease.<br><b>METHODS</b>: In this non-randomised, single-centre, open-label, phase 2 trial, adult patients with clinical manifestations of von Hippel-Lindau disease were recruited from the University of Texas MD Anderson Cancer Center (Houston, TX, USA) and were treated with pazopanib (800 mg orally daily) for 24 weeks, with an option to continue treatment if desired by the patient and treating physician.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30236511",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "This study is registered with ClinicalTrials.gov, number NCT01436227, and is closed to accrual.<br><b>FINDINGS</b>: Between Jan 18, 2012, and Aug 10, 2016, we screened 37 patients with genetically confirmed or clinical features consistent with von Hippel-Lindau disease, of whom 31 eligible patients were treated with pazopanib.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30236511",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Treatment-related serious adverse events included one case each of appendicitis and gastritis and one patient had a fatal CNS bleed.<br><b>INTERPRETATION</b>: Pazopanib was associated with encouraging preliminary activity in von Hippel-Lindau disease, with a side-effect profile consistent with that seen in previous trials.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30236511",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Pazopanib could be considered as a treatment choice for patients with von Hippel-Lindau disease and growing lesions, or to reduce the size of unresectable lesions in these patients.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30236511",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "We aimed to assess the activity and safety of pazopanib in patients with von Hippel-Lindau disease.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30236511",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In this non-randomised, single-centre, open-label, phase 2 trial, adult patients with clinical manifestations of von Hippel-Lindau disease were recruited from the University of Texas MD Anderson Cancer Center (Houston, TX, USA) and were treated with pazopanib (800 mg orally daily) for 24 weeks, with an option to continue treatment if desired by the patient and treating physician.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30236511",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Pazopanib was associated with encouraging preliminary activity in von Hippel-Lindau disease, with a side-effect profile consistent with that seen in previous trials.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30236511",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Pazopanib could be considered as a treatment choice for patients with von Hippel-Lindau disease and growing lesions, or to reduce the size of unresectable lesions in these patients.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30236511",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Between Jan 18, 2012, and Aug 10, 2016, we screened 37 patients with genetically confirmed or clinical features consistent with von Hippel-Lindau disease, of whom 31 eligible patients were treated with pazopanib.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30236511",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "Yes"
}